AMENDED AND RESTATED INVESTOR RIGHTS’ AGREEMENTInvestor Rights Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is entered into this 13th day of March, 2008 by and between VASCULAR BIOGENICS LTD., an Israeli private company No. 51-289976-6 (the “Company”), the holders of Series A Preferred Shares of the Company, NIS 0.01 par value each (the “Preferred A Shares” and “Preferred A Shareholders” respectively), the holders of Series B Preferred Shares of the Company (the “Preferred B Shares” and “Preferred B Shareholders” respectively), the holders of Series C Preferred Shares of the Company ((the “Preferred C Shares” and “Preferred C Shareholders” respectively), and the holders of Series D Preferred Shares of the Company (the “Preferred D Shares” and “Preferred D Shareholders” respectively). The Preferred A Shareholders, Preferred B Shareholders, Preferred C Shareholders and Preferred D Shareholders, shall be referred to herein as the “Preferred Shareholders” and the Preferred A Shares, Preferred B Shares, Preferred C Shares an
TECHNICAL AGREEMENT ON THE MANUFACTURE OF CAPSULES for VASCULAR BIOGENICSTechnical Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations
AGREEMENTCollaboration Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations
Tel Hashomer - Medical Research, Infrastructure and Services Ltd., a private company duly incorporated under the laws of the State of Israel having its registered office at Tel Hashomer, Israel, 52621, represented by its authorized representatives (“THM”); and
TECHNICAL AGREEMENT ON THE MANUFACTURE OF CAPSULES VB-201 for VASCULAR BIOGENICSTechnical Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations
AGREEMENTIntellectual Property Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations
THIS AGREEMENT is made and entered into as of this 24 day of January, 2010 by and between Vascular Biogenics Ltd., a company registered under the laws of the State of Israel (“VBL”) and Prof. Jacob George (“George”);
Unprotected lease AgreementLease Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations
GENERAL SERVICES AGREEMENT BioClinica Agreement #40801General Services Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations • England
This General Services Agreement (this “Agreement”) effective as of the last date of signature hereof (the “Effective Date”), by and between BioClinica, Inc., a Delaware Corporation, with its principal place of business at 826 Newtown-Yardley Road, Newtown, Pennsylvania, 18940-1721 (“BIOCLINICA”) and Vascular Biogenics Ltd. with its principal place of business at 6 Jonathan Netanyahu Street, Or Yehuda, Israel 60376 (“VASCULAR BIOGENICS”). BIOCLINICA and VASCULAR BIOGENICS are individually referred to as a “Party” and collectively as the “Parties”.
MATERIAL TRANSFER AND CONFIDENTIALITY AGREEMENTMaterial Transfer and Confidentiality Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations
Crucell Holland B.V., a Dutch company with offices located at Archimedesweg 4, 2333 CN, Leiden, the Netherlands, hereinafter referred to as “CRUCELL”; and
SERVICE AGREEMENT FOR A CLINICAL STUDY CONDUCTService Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations • England
KCR S.A. (Polish joint-stock company) with its registered office in Warsaw at 6 Postępu Str., 02-676 Warsaw, Poland, entered in the register of entrepreneurs kept by the District Court for the Capital City of Warsaw in Warsaw, 13th Commercial Division of the National Court Register, under number 0000289542, tax identification number NIP: 521-31-69-665, share capital (covered in total): PLN 700,000.00, hereinafter referred to as “CRO”, represented by Mr. Adam Kruszewski – President of the Management Board,
MANUFACTURING SERVICES AGREEMENTManufacturing Services Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations • England and Wales
This Manufacturing Services Agreement (the “Agreement”) is made as of January 5, 2012, (the “Effective Date”) between Lonza Houston, Inc., a Delaware corporation having its principal place of business at 8066 El Rio St., Houston, TX 77054 (“LHI”), and Vascular Biologics, Ltd., an Israeli corporation, having an office at 6 Jonathan Netanyahu St., Or Yehuda, Israel 60376 (“CLIENT”) (each of LHI and CLIENT, a “Party” and, collectively, the “Parties”).
MASTER SERVICES AGREEMENTMaster Services Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations
The terms stated in this Master Services Agreement (“Agreement”) are agreed to apply to all projects performed in the past and after the date hereof for Vascular Biogenics, Ltd. located at 6 Jonathan Netanyahu Street, Or Yehuda, 60376, Israel (hereinafter referred to as “Client”), by Genzyme Pharmaceuticals., located at Eichenweg 1, CH-4410 Liestal, Switzerland (hereinafter referred to as “Contractor”).
SERVICE AGREEMENT FOR A CLINICAL STUDY CONDUCTService Agreement • June 6th, 2014 • Vascular Biogenics Ltd. • Pharmaceutical preparations • England
KCR S.A. (Polish joint-stock company) with its registered office in Warsaw at 6 Postępu Str., 02-676 Warsaw, Poland, entered in the register of entrepreneurs kept by the District Court for the Capital City of Warsaw in Warsaw, 13th Commercial Division of the National Court Register, under number 0000289542, tax identification number NIP: 521-31-69-665, share capital (covered in total): PLN 700,000.00, hereinafter referred to as “CRO”, represented by Mr. Mike Jagielski – President of the Management Board and Ms. Anna Baran – Vice President of the Management Board,
